JAK2 and acquired polycythemia vera: Marubayashi et al. reported a HSP90 inhibitor that can disrupt Jak2 protein stability in polycythemia vera, suggesting that the Jak2 V617F mutation depends on HSP90 for its constitutive activity [23].